

ASSESSMENT OF SERUM URIC ACID AS A MARKER IN HYPERTENSIVE PATIENTS

Tahreem Arshad^{*1}, Mahnoor Waseem², Waqas Zafar³, Miss Sidra Jabeen⁴,
Miss Bakhtawar Malik⁵, Syed Sami Ahmad bukhari⁶, Amna Noor⁷

^{*1,2,3}Faculty Of Allied Health Sciences Superior University Lahore, Sargodha Campus

^{4,5}Lecturer, Faculty of Allied Health Sciences Superior University Lahore, Sargodha Campus

⁶Lecturer, PhD Scholor, Faculty of Allied Health Sciences Superior University Lahore

⁷Phd Scholar, Faculty of Allied Health Sciences, Superior University Lahore

⁶samibukhari79@gmail.com

DOI: <https://doi.org/10.5281/zenodo.20507997>

Keywords**Article History**

Received: 02 April 2026

Accepted: 12 May 2026

Published: 30 May 2026

Copyright @Author

Corresponding Author: *

Tahreem Arshad

Abstract

Introduction: Hypertension is a serious public health problem in the entire world and one of the leading causes of morbidity and mortality associated with cardiovascular and renal disorders. Recent studies suggest that SUA might play a critical role in the development and progression of hypertension. Therefore, this particular study has been undertaken to identify serum uric acid as a predictor for hypertensive subjects.

Materials and Methods: This was a cross-sectional study done at the Department of Pathology/Clinical Laboratory, City Care Lab, Sargodha. There were 343 subjects comprising normotensive and hypertensive subjects. Demographic and clinical data were recorded by means of a structured questionnaire. Levels of serum uric acid were determined by the Enzymatic Colorimetry method which is also referred to as the Uricase-Peroxidase method. After the venous blood samples were collected under aseptic technique, the collected data were analyzed using SPSS software. The appropriate tests were applied, and a value of $p \leq 0.05$ was considered statistically significant.

Result: It was found that the mean serum uric acid value in patients with hypertension was significantly higher (7.42 ± 2.44 mg/dL) when compared to that in patients with normal blood pressure (5.73 ± 2.79 mg/dL). In addition, there was also a considerable positive relationship between serum uric acid and systolic blood pressure ($r = 0.283$, $p = 0.001$) as well as diastolic blood pressure ($r = 0.277$, $p = 0.001$). This finding suggests that elevated serum uric acid levels may be associated with hypertension.

Conclusion: As a whole, the results of this study demonstrate a significant correlation between serum uric acid levels and hypertension. The latter factor could be a good, simple, and cost-effective marker for the diagnosis and management of hypertensive individuals. To examine the clinical significance and associations between serum uric acid and hypertension, further studies are recommended.

CHAPTER 1 INTRODUCTION

Introduction to Hypertension

High blood pressure, often known as hypertension, is a chronic medical illness marked by chronically increased arterial blood pressure levels beyond typical physiological ranges. The force that circulating blood applies to the walls of blood vessels is known as blood pressure, and it is normally assessed using systolic blood pressure (SBP) and diastolic blood pressure (DBP). During cardiac contraction, systolic pressure is measured, whereas during cardiac relaxation, diastolic pressure is measured. Excessive strain on blood arteries and vital organs might result in dangerous health problems due to these continuously high readings. Because of its close relationship with cardiovascular and renal disorders, hypertension is considered one of the most crucial avoidable causes of disease and death globally.⁽¹⁾

It is seen as a significant worldwide public health issue that affects people of all ages and populations. It is believed that hypertension affects over a billion people globally, with its prevalence still increasing due to population expansion, urbanization, aging, a sedentary lifestyle, unhealthy eating habits, obesity, smoking, too much salt consumption, and psychological stress. Hypertension is especially problematic in low- and middle-income nations because diagnosis, treatment, and awareness are still subpar. High blood pressure can be known as the “silent killer” since it takes time to develop and causes no visible signs, leading to a late diagnosis in most cases.⁽²⁾

The identification of high blood pressure is mostly accomplished by taking several blood pressure measurements that exceed predetermined clinical limits. In order to assist with treatment and diagnosis, hypertension is categorized by blood pressure values in accordance with a number of international standards. Vascular remodeling, endothelial dysfunction, and increased arterial stiffness are all caused by chronic uncontrolled hypertension, which leads to structural and functional changes in blood vessels. Finally, these physiological alterations raise the heart's workload and worsen organ damage.⁽³⁾

Many problems that affect several organ systems have a strong link to hypertension. Significant increases in the risk of cardiovascular illnesses such as coronary artery disease, myocardial infarction, heart failure, and left ventricular hypertrophy are caused by persistently high blood pressure. In addition, hypertension is a significant factor in cerebrovascular conditions such as transient ischemic attacks and stroke. In addition to cardiac problems, chronic hypertension can damage renal function, resulting in chronic kidney illness and, eventually, renal failure. These factors greatly raise the cost of health care, the rate of disability, and the death rate globally.⁽⁴⁾

This condition poses serious issues due to its complex nature and many causes, despite advancements in diagnosis and treatment options. This means that researchers are still investigating a number of biochemical parameters that can assist in improving the diagnosis, risk assessment, and prediction of complications associated with hypertension. These markers could be very useful in the effective management and prevention of hypertension.⁽⁵⁾

Hypertension's Risk Factors and Causes

The development of hypertension is an outcome of a multi-level process caused by exposure to the environment, behavioral aspects, physiological defects, and genes. Proper functioning of different systems, including cardiovascular, renal, endocrine, and nervous, is crucial in maintaining healthy blood pressure. Disturbance of the regulating mechanisms may cause an elevated level of blood pressure, leading to hypertension. Usually, hypertension develops slowly in most cases over the period of several years, making it undiagnosed for long periods of time due to asymptomatic nature at early stages. There exist two main types of hypertensions namely; primary or essential hypertension and secondary hypertension. Primary or essential hypertension constitutes up to 90 to 95 percent of all hypertension cases and normally occurs in the absence of a known cause whereas secondary hypertension arises due to some other pathologic condition. Hypertension's rising cases around the world are an indication of urbanization, changes

in lifestyles, dietary modifications, increase in age of population, and obesity cases.⁽⁶⁾

Because multiple genes involved in blood pressure regulation impact susceptibility to elevated blood pressure, genetic factors play a large part in the etiology and development of hypertension. Compared to those who do not have a family history of hypertension, those who do have a family history are typically at a higher risk. Among the physiological systems affected by genetic variables are sodium transport, renal electrolyte management, vascular resistance, hormonal pathways, sympathetic nervous system function, and endothelial function. However, whether hypertension develops is determined by interactions between inherited factors and environmental exposures, not by genetic propensity alone. Hypertension is a polygenic disorder that impacts several biological pathways, according to research, since it is caused by the simultaneous interaction of multiple gene variations. Because those with hereditary susceptibility may gain from earlier preventative treatments and risk assessment approaches, understanding genetic impacts is still essential.⁽⁷⁾

Aging causes progressive structural and functional alterations in blood vessels, making increasing age one of the most significant non-modifiable risk factors linked to hypertension. As a result of collagen deposition, vascular remodeling, and decreased compliance of arterial walls, arteries progressively become less elastic as people age. Systolic blood pressure rises as a result of these changes, which also raise peripheral vascular resistance. Additionally, mechanisms governing blood pressure control are additionally hampered by age-related changes in endothelial function, hormonal activity, renal function, and autonomic regulation. Hypertension prevalence disparities related to gender have also been seen. While decreasing estrogen levels lower vascular protection and promote endothelial dysfunction and arterial stiffness in women after menopause, men often exhibit greater prevalence during early adulthood due to hormonal and lifestyle influences. As a result, aging populations significantly add to the rising worldwide hypertension burden.⁽⁸⁾

One of the most important changeable risk variables for the development of hypertension is obesity and overweight. Blood pressure levels are increased by several physiological defects that are caused by too much adipose tissue. Elevated cardiac output, increased sodium retention, and vasoconstriction are brought on by an increase in body fat, which also stimulates the renin-angiotensin-aldosterone system and the sympathetic nervous system. Furthermore, altered adipokine synthesis, oxidative stress, endothelial dysfunction, insulin resistance, and chronic inflammation are all factors that are exacerbated by obesity and have a detrimental impact on cardiovascular regulation. In addition, extra body weight puts more strain on the cardiovascular system and raises metabolic demands. Consistently, epidemiological studies show a high positive correlation between the prevalence of hypertension and body mass index, and waist circumference, underscoring the significance of weight control approaches in programs for hypertension prevention and management.⁽⁹⁾

Dietary factors play a crucial role in blood pressure regulation and are important contributors to the onset of hypertension. High blood pressure levels are caused by excessive sodium consumption, which also promotes fluid retention and raises circulating blood volume. Excessive sugar, refined carbohydrates, saturated fats, and processed meals promote inflammation, vascular dysfunction, metabolic abnormalities, and obesity, all of which raise the risk of hypertension. Insufficient potassium, calcium, magnesium, fruit, vegetable, and dietary fiber consumption may impair vascular relaxation and electrolyte balance processes. Beyond leading to hypertension, excessive caloric consumption and bad eating habits also aid in the advancement of cardiovascular problems. Nutritional treatments are important parts of hypertension prevention methods since dietary habits may be changed.⁽¹⁰⁾ Hypertension development and progression are greatly influenced by a number of lifestyle choices, such as psychological stress, alcoholism, smoking, and physical inactivity. Obesity, compromised endothelial function, metabolic problems that raise blood pressure, and decreased cardiovascular

efficiency are all caused by physical inactivity. Maintenance of a healthy body weight, increased insulin sensitivity, decreased sympathetic activation, and improved vascular function are all benefits of regular physical exercise. Nicotine-induced vasoconstriction, increased sympathetic stimulation, endothelial damage, inflammation, and oxidative stress are all ways that smoking causes hypertension. Excessive alcohol consumption might likewise increase blood pressure by affecting vascular regulation mechanisms and neurohormonal pathways. Additionally, prolonged activation of the sympathetic nervous system and higher release of stress hormones like cortisol and catecholamines exacerbate chronic psychological stress. These behavioral variables all contribute significantly to an increased risk of hypertension and poorer disease outcomes.⁽¹¹⁾

Most instances of hypertension are caused by essential hypertension; however secondary hypertension develops as a result of underlying medical problems. Because kidneys play important roles in controlling blood pressure and fluid balance, renal disorders are among the most frequent causes. Hormone disturbances affecting the regulation of blood vessel tone and electrolyte imbalance could also contribute to secondary causes of diseases like hyperthyroidism, hypothyroidism, Cushing's syndrome, primary aldosteronism, and pheochromocytoma. Other examples include obstructive sleep apnea, vascular conditions, neuromuscular problems, and certain medications like corticosteroids and oral contraceptives. Since addressing the secondary cause will likely improve control over hypertension, making its diagnosis remains an important clinical step. The involvement of a number of factors suggests that hypertension is a complex problem with complicated physiological mechanisms at play instead of a one-cause disease.⁽¹²⁾

Hypertension complications

The reason for this is the development of significant changes in the vascular system and organs due to long-term exposure of the body to increased arterial blood pressure. Constant

mechanical stress damages the endothelial cells that line blood vessels, promotes vascular remodeling, increases arterial stiffness, and quickens the development of atherosclerotic plaques. Target organs including the heart, brain, kidneys, eyes, and peripheral circulation are progressively damaged by these pathological changes, which impair tissue perfusion. Many people develop problems before diagnosis or treatment since hypertension is typically asymptomatic during its early stages. Therefore, hypertension continues to be one of the most common preventable causes of death and disability globally.⁽¹³⁾

Because high blood pressure pushes the heart to labor against higher vascular resistance, cardiovascular problems are among the most serious side effects of chronic hypertension. Adaptive structural changes, such as left ventricular hypertrophy, which is defined by a thickening of the heart muscle fibers, are a result of chronic overload. Even if these changes are at first compensatory, they gradually cause heart function to worsen and raise the risk of heart failure, ischemia, and arrhythmias. Damaging the vascular endothelium and supporting plaque formation in coronary arteries, hypertension also hastens the growth of atherosclerosis. These processes raise the likelihood of congestive heart failure, sudden cardiac death, myocardial infarction, and coronary artery disease. Because cardiovascular issues are the main cause of fatalities worldwide, maintaining blood pressure regulation is crucial for lowering disease burden.⁽¹⁴⁾

Because high blood pressure impairs cerebral circulation and harms cerebral blood vessels, cerebrovascular issues are also highly connected to hypertension. Increased vulnerability to rupture, thrombosis, vessel wall weakening, and atherosclerotic constriction are all results of chronic vascular damage. Hence, hypertension is among the most potent risk factors for ischemic and hemorrhagic stroke. Chronic hypertension causes microvascular abnormalities that affect brain structure, reduced cerebral perfusion, white matter damage, and impaired neuronal function in addition to strokes. These modifications might

cause memory loss, poor cognitive function, vascular dementia, and damaged neurological function. Neurological difficulties have a major impact on quality of life and may lead to lasting disability in those who are afflicted.⁽¹⁵⁾

Given that vascular integrity and filtration processes are crucial to the kidneys, hypertensive damage is particularly detrimental to them. Kidney function is gradually diminished by persistent high blood pressure, which harms the glomerular structures responsible for filtration and the blood vessels in the kidneys. These changes eventually result in proteinuria, a reduced glomerular filtration rate, chronic kidney disease, and end-stage renal failure, which necessitates dialysis or kidney transplantation. Also, impairment of kidney functions aggravates hypertension because of their inability to regulate fluid balance and electrolyte homeostasis. Such a bidirectional relationship between kidney disease and hypertension creates a vicious circle, accelerating the process of disease development and increasing mortality rate.⁽¹⁶⁾

Progressive vascular damage also causes hypertension to impact the ocular and peripheral vascular systems. Increased blood pressure damages the retinal blood vessels, resulting in vascular constriction, bleeding, retinal edema, cotton wool spots, and decreased retinal circulation, leading to hypertensive retinopathy. Blurred eyesight or irreversible vision damage may result from extreme situations. Additionally, accelerated atherosclerosis and endothelial dysfunction in peripheral vessels are caused by high blood pressure, which also contributes to peripheral arterial disease. Reduced blood flow to extremities may result in pain, impaired mobility, ischemic tissue damage, and an elevated risk of vascular problems. Early identification, risk factor modification, and efficient management techniques for hypertension prevention and control are highlighted by these common consequences.⁽¹⁷⁾

Uric Acid Overview

Purines in the human body are broken down, resulting in the creation of uric acid, a naturally occurring metabolic product. Purines are naturally

occurring nitrogen-containing chemicals that are crucial ingredients of nucleic acids like DNA and RNA and may be found in the body via cellular metabolism and in the diet. Uric acid is generated through a number of enzymatic processes, with xanthine oxidase playing a significant role in changing hypoxanthine and xanthine into uric acid, as a result of the metabolism of purines. Humans do not have the enzyme uricase, which converts uric acid into more soluble chemicals, as is the case in several other animals, thus uric acid is the end product of purine metabolism in humans. As a result, serum uric acid levels in humans are greater than those in other species.⁽¹⁸⁾

The equilibrium between uric acid production and elimination dictates the concentrations of uric acid in the blood. Around two-thirds of the uric acid made in the body is eliminated through the kidneys under normal physiological circumstances, and the remaining portion is excreted through the gastrointestinal tract. Via glomerular filtration, tubular reabsorption, secretion, and post-secretory reabsorption, the kidneys are essential for preserving uric acid homeostasis. Abnormal serum uric acid levels can be caused by any disruption that interferes with the production or excretion processes. Hyperuricemia is defined by serum uric acid levels above the normal physiological ranges and can be caused by increased synthesis, decreased excretion, or a combination of the two.⁽¹⁹⁾

The average concentration of uric acid in the serum depends on a variety of things, including the individual's age, gender, eating habits, kidney function, and metabolic state. Since estrogen encourages uric acid excretion in females, adult males often exhibit greater serum uric acid levels than females. Increased intake of purine-rich foods, consumption of alcohol, obesity, insulin resistance, hereditary predisposition, and renal dysfunction may all have an impact on serum uric acid levels. The measurement of serum uric acid has become crucial in assessing different metabolic and cardiovascular disorders as a result of the numerous physiological and pathological elements that influence uric acid metabolism.⁽²⁰⁾

Uric acid has previously been associated with gout and kidney stones because it is responsible for the

formation of crystals. But nowadays, uric acid is increasingly becoming known as an organ that has other biological roles other than causing illnesses as a result of crystal formation. Uric acid, according to studies, is involved in inflammatory responses, oxidative processes, the control of endothelial function, and vascular homeostasis. Even though uric acid can act as an antioxidant in some circumstances by removing reactive oxygen species, high quantities may paradoxically lead to cellular malfunction and oxidative stress. Growing curiosity has arisen regarding the association between chronic disorders like hypertension, diabetes mellitus, metabolic syndrome, cardiovascular disease, and chronic kidney disease and serum uric acid due to this dual function.⁽²¹⁾

According to current research, high serum uric acid levels may cause cardiovascular dysfunction via a variety of biological processes, such as endothelial impairment, inflammatory pathway activation, elevated oxidative stress, vascular smooth muscle proliferation, and renin-angiotensin system stimulation. Vascular damage and blood pressure control may be caused by these mechanisms. As a result, serum uric acid has been studied more and more as a possible biomarker for predicting cardiovascular risk and pinpointing persons who are more susceptible to hypertension and other problems. Therefore, it is still crucial to understand uric acid physiology and metabolism in order to assess its potential contribution to the onset and progression of illness.⁽²²⁾


Relationship of Hypertension to Uric Acid

Due to several clinical, experimental, and epidemiological studies implying that increased uric acid levels may contribute to the emergence and advancement of high blood pressure, the association between serum uric acid and hypertension has drawn more attention. Though hyperuricemia has long been associated with gout and metabolic disorders, recent research suggests

that higher serum uric acid levels may have a significant role in cardiovascular diseases, especially hypertension. According to a number of population-based studies, persons with high serum uric acid levels are more prone to acquire hypertension than individuals with normal uric acid levels. Regarding the possible function of serum uric acid as both a risk factor and a biomarker for hypertension, this association has aroused a great deal of interest.⁽²³⁾

Endothelial dysfunction is one suggested explanation for the connection between uric acid and hypertension. Nitric oxide generation, blood flow, and vascular tone are regulated by the vascular endothelium, which is crucial for maintaining normal blood pressure. Increased oxidative stress within vascular tissues and a decrease in nitric oxide bioavailability may lead to endothelial dysfunction caused by elevated serum uric acid levels. Ultimately contributing to increased blood pressure, decreased nitric oxide availability leads to increased vascular resistance and decreased vasodilation. As a result, hyperuricemia and the development of hypertension are thought to be closely related since endothelial dysfunction is a critical early event.⁽²⁴⁾

The link between serum uric acid and hypertension is further clarified by oxidative stress and inflammation. High uric acid levels may promote the creation of reactive oxygen species and trigger inflammatory pathways that contribute to vascular damage. Pathological changes like vascular remodeling, stiffening of arteries, and constriction of blood vessels occur due to the inflammatory process that occurs within the blood vessels. Persistent rise in blood pressure will be compounded by these pathological changes, as well as the increase in vascular resistance. In addition, inflammation associated with hyperuricemia may exacerbate vascular injury.⁽²⁵⁾



Another key method entails the activation of the Renin-Angiotensin-Aldosterone System (RAAS), which is responsible for regulating blood pressure. Based on research findings, elevated uric acid levels have been known to activate renin, leading to the stimulation of RAAS components, leading to increased salt retention, vasodilation, and accumulation of extracellular fluid. The gradual onset of hypertension and the constant rise in blood pressure are associated with the hormonal process that is activated. Consequently, high uric acid levels can influence the regulation of blood pressure using the hormonal and renal approach ⁽²⁶⁾.

Since the kidneys regulate blood pressure and the uric acid balance, renal mechanisms become important to consider when looking into the link between uric acid and high blood pressure. Renal microvascular damage and decreased renal blood flow may be caused by hyperuricemia, which would limit the kidneys' ability to properly control fluid excretion and sodium balance. Salt sensitivity and sustained hypertension may be exacerbated by renal vascular damage brought on by high uric acid levels. In contrast, hypertension can also affect kidney function and lower uric acid excretion, establishing a two-way connection between high blood pressure and serum uric acid levels. ⁽²⁷⁾

Many observational and longitudinal studies have shown substantial relationships between high serum uric acid levels and a higher incidence of hypertension in various populations. Even after accounting for common risk factors like obesity, age, and metabolic problems, research indicates that those who have hyperuricemia may be more likely to get hypertension. Nevertheless, there is ongoing discussion on whether high uric acid operates as a autonomous cause or just represents underlying metabolic problems related with hypertension, even if there is strong evidence to back up this link. However, increasing evidence indicates that serum uric acid may offer clinically valuable data for assessing cardiovascular risk and predicting hypertension. ⁽²⁸⁾


The identification of an increase in uric acid levels can be used to detect individuals who have an increased risk of developing cardiovascular disease, thus making the association between serum uric acid and hypertension medically relevant. Given that serum uric acid levels are easily measurable, cost-effective, and widely available in many clinical labs, it has gained considerable attention as a potential marker for people suffering from hypertension. Understanding the relationship between hyperuricemia and hypertension can, therefore,

assist in formulating better preventive measures, early diagnosis, and treatment of hypertension. ⁽²⁹⁾

Uric Acid in the Serum as a Marker

There has been increasing interest in studying serum uric acid in a number of diseases, including some metabolic disorders, as well as cardiovascular disease, notably hypertension. A biomarker is a measurable biological indicator that reflects physiological or pathological processes in the body. Since serum uric acid is easily assessed in

routine laboratory tests, its capacity to represent metabolic dysfunction, oxidative stress, and renal handling abnormalities has been extensively examined. It's possible that blood levels of it might offer helpful information regarding disease risk, course, and severity, particularly in diseases characterized by metabolic and vascular disorders. Due to its accessibility, affordable cost, and widespread usage in clinical labs, serum uric acid has emerged as a potential risk assessment candidate for hypertensive individuals. ⁽³⁰⁾



High blood pressure is consistently linked to raised levels of serum uric acid, hence it is regarded as a potential predictive biomarker in the context of hypertension. According to research, uric acid may indicate the first vascular alterations linked to hypertension, such as endothelial dysfunction, increased oxidative stress, and the activation of inflammatory pathways. Therefore, even before clinical signs of hypertension manifest, high uric acid levels may be a sign of ongoing pathological processes. As a result, serum uric acid may be a useful biomarker for identifying those who are likely to get hypertension and cardiovascular problems in the early stages. ⁽³¹⁾

Serum uric acid is not yet considered a definitive diagnostic biomarker for hypertension because there is still a discussion about its causal vs. associative role, even though it may be beneficial. Other research indicates that high uric acid may

just be a sign of underlying metabolic diseases like obesity, insulin resistance, and renal impairment, despite the fact that a number of studies support its independent relationship with hypertension. However, its possible function as a supportive biomarker in clinical practice is supported by its powerful and consistent connection with hypertension across numerous populations. More studies are required to define its precise function and assess whether it may be successfully employed in routine screening and risk stratification of hypertensive patients. ⁽³²⁾

Literature Background

A lot of research has been done to examine the link between hypertension and serum uric acid, and the results of epidemiological, clinical, and experimental investigations often point to a good correlation between high blood pressure and high

uric acid levels. Individuals who have elevated serum uric acid levels are more likely to develop hypertension over time than those who have normal levels, according to large population-based research. In addition, longitudinal cohort studies have shown that high levels of uric acid can precede the onset of hypertension, suggesting that it plays an active role in the early stages of disease development, and is not just a consequence of hypertension. Researchers have been encouraged to explore serum uric acid as a predictor of hypertension based on these results.⁽³³⁾

In addition, efforts have been made to explore the biology behind this connection through experiments and clinical trials. Evidence indicates that uric acid may cause high blood pressure by causing vascular inflammation, oxidative stress, endothelial dysfunction, and activation of the renin-angiotensin system. Furthermore, supporting a potential causal connection, animal research has shown that hyperuricemia brought about by experimentation can result in elevated blood pressure and vascular alterations. However, a number of clinical trials have indicated that the link may be affected by numerous overlapping risk factors, showing that the connection becomes less pronounced after controlling for confounding factors like obesity, renal function, and metabolic syndrome.⁽³⁴⁾

In addition, systematic reviews and meta-analyses have been carried out to provide a more thorough knowledge of the relationship between hypertension and serum uric acid. A considerable positive link between serum uric acid levels and the risk of developing hypertension is typically found in these studies. However, they also bring to light differences across research designs, adjustment factors, and populations. The exact clinical significance of this parameter as an independent predictor may still be evaluated, however, the available literature suggests that uric acid may play a substantial role in cardiovascular risk stratification.⁽³⁵⁾

Research Gap

Many gaps remain in the current research despite substantial worldwide research on the link between hypertension and serum uric acid. The

absence of reliable data demonstrating whether serum uric acid functions as an independent causal component for hypertension or just indicates underlying metabolic and kidney problems is a significant gap. Although many research indicate a strong correlation, its intensity varies depending on confounding variables like lifestyle factors, diet, renal function, and body mass index, which causes uncertainty in clinical interpretation.⁽³⁶⁾

Another significant deficiency is the scarcity of population-specific information, especially in developing nations where access to healthcare, environmental exposure, genetic background, and dietary practices may be markedly different from the groups researched in Western nations. Limited local research has been done to assess serum uric acid as a biomarker in hypertensive patients in countries like Pakistan, making it difficult to apply global discoveries to the local population. Thus, in order to gain a better understanding of this link in other demographic and clinical settings, region-specific research is required.⁽³⁷⁾

Moreover, there are no established cutoff points for serum uric acid to be employed as a diagnostic or prognostic indicator for hypertension. Since various studies have utilized different criteria, it is difficult to create a universally accepted clinical guideline. In addition, the majority of current studies are cross-sectional in nature, which makes it difficult to establish temporal or causal correlations. Additional prospective and longitudinal research is still needed to ascertain whether high serum uric acid can accurately predict the onset or advancement of hypertension. In order to improve our knowledge of the clinical importance of serum uric acid and its possible part in the treatment of hypertension, these holes must be addressed.⁽³⁸⁾

Rationale of the Study

One of the most important non-communicable illnesses in the world and a major cause of cardiovascular, cerebrovascular, and kidney morbidity and mortality is hypertension. This condition is often called “the silent killer” as it usually progresses with no evident symptoms at all, making the condition have ample opportunities to

damage the vital organs in an increasingly harmful way. Patients usually get diagnosed when it's already too late, leading to problems such as stroke, myocardial infarction, or even chronic kidney disease. A large group of patients still suffer from blood pressure that remains high despite the presence of highly efficient medicines for this condition due to its detection at late stages and the absence of early warning signs. Thus, the necessity for reliable laboratory tests, which would help in identifying individuals at risk and improve patient treatment options, gets emphasized.

Uric acid serum concentration has increasingly come into focus in the last couple of years as a promising biomarker linked to hypertension and cardiovascular disease risk. The kidneys are responsible for the majority of uric acid excretion, which is the end product of purine metabolism. Even though it has historically been associated with gout and the development of kidney stones, mounting evidence points to its role in metabolic regulation and vascular biology. Reduced nitric oxide availability, oxidative stress, vascular inflammation, and endothelial dysfunction have all been connected to high serum uric acid levels. The development of hypertension is heavily reliant on the key mechanisms of impaired vasodilation and increased peripheral vascular resistance, both of which can result from these pathological changes. Furthermore, uric acid has been connected to the renin-angiotensin-aldosterone system activation, which provides additional support for its possible role in cardiovascular pathology and blood pressure control.

There is still much debate over the precise function of increased serum uric acid in the genesis of disease, despite the growing body of research proving a connection between it and hypertension. The question still lingers on whether uric acid is simply a consequence of another metabolic condition such as obesity, insulin resistance, dyslipidemia, or reduced renal function, or whether uric acid itself serves as an additional cause. Some literature shows that the association tends to substantially weaken when controlling for other factors while others show a significant association regardless of controlling for such factors. The use of the finding in question in

clinical practice as an established biomarker has been hindered by inconsistency across several groups. Furthermore, hypertension diagnoses and prognoses currently fail to consider serum uric acid, thereby requiring further research prior to its implementation.

That is precisely why the study of serum uric acid among hypertensive individuals is important, particularly when the data about such a population are scarce. Socioeconomic factors, availability of health services, environmental influences, nutrition, and genetic make-up are factors that may strongly affect both the prevalence of hypertension and serum uric acid concentrations. Therefore, the findings of international research may not always be directly relevant to the local population. Evidence from the area is needed in nations like Pakistan, where hypertension is extremely common and frequently not well controlled, in order to better comprehend the connection between serum uric acid and hypertension in this particular demographic. Whether population-specific differences exist or whether serum uric acid behaves likewise as a risk predictor in the local environment may be determined with the aid of such data.

This study aims to assess serum uric acid as a possible laboratory indicator in hypertensive individuals and to examine its connection with the existence and potential severity of hypertension. The study intends to investigate if serum uric acid levels can help identify risk early on and enhance clinical evaluation by examining affected people's levels. Routine lab testing may incorporate serum uric acid as a simple, affordable, and readily accessible biomarker if a strong and consistent relationship is seen. This could eventually help the doctors in identifying the high-risk patients early and even reduce the number of cases of hypertension by adopting better ways of dealing with the disease.

CHAPTER 2 LITERATURE REVIEW

Studies done in 2026 on cohort samples have added weight to the evidence on the predictive effect of serum uric acid on the onset of hypertension. According to these investigations,

healthy people with higher baseline uric acid levels were substantially more likely to acquire hypertension than those with normal levels. This indicates that even before clinical hypertension is apparent, serum uric acid may function as an early metabolic and vascular marker. The proposed mechanism entails an early endothelial dysfunction, whereby increased uric acid decreases nitric oxide availability, resulting in decreased vasodilation and increased vascular resistance. Moreover, it is thought that low-grade inflammation and oxidative stress are essential to the development of vascular damage. Elevated blood pressure and increasing arterial stiffness are caused over time by these preliminary alterations. As a result, uric acid is increasingly regarded as a potential factor in the early onset of hypertension as well as a biomarker.⁽³⁹⁾

Strong pooled evidence has been presented in systematic reviews and meta-analyses published in 2025 regarding the link between serum uric acid and hypertension. Data from a number of cohort and observational research conducted in different countries and populations are merged in these studies. In general, individuals with greater serum uric acid levels have a considerably higher chance of having hypertension, according to the research. The association persists to be statistically significant even after controlling for major confounding variables like age, body mass index, renal function, and lifestyle variables. These studies, however, also indicate differences in effect size across populations, implying that dietary, environmental, and genetic variables all affect this association. According to some studies, uric acid may have a more significant role in the development of early-onset hypertension since younger people have more robust associations. Despite these differences, the general finding supports a beneficial and clinically relevant link between hypertension and uric acid.⁽⁴⁰⁾

Hypertensive patients have been shown to have greater serum uric acid levels than normotensive people in clinical comparative studies conducted in 2025. These studies indicate that early vascular alterations, which raise blood pressure, may be connected to hyperuricemia. Endothelial dysfunction is one of the main methods that have

been suggested; in this condition, uric acid decreases nitric oxide synthesis, which results in diminished vascular relaxation. Moreover, endothelial cells are further damaged and inflammation within the vascular system is encouraged by elevated oxidative stress. Additionally, hypertensive people experience decreased renal uric acid excretion, which results in blood buildup. These mixed effects imply that serum uric acid is related to hypertension and may also indicate the underlying pathophysiological processes involved in its onset.⁽⁴¹⁾

In 2024, cross-sectional research looked at the association between hypertension seriousness and serum uric acid levels. Patients with more severe hypertension have been shown to have greater serum uric acid levels, according to these studies. This indicates that uric acid content and blood pressure levels may be connected in a dose-response manner. The levels of uric acid increase significantly as the progression of hypertension moves from stage one to two based on the study. This may be due to worsening vascular dysfunction and the deterioration of the kidneys brought about by the progression of hypertension. High levels of uric acid may also be due to the inflammation experienced and the stiffening of the arteries.⁽⁴²⁾

From the findings made in 2024 involving the study of metabolic syndrome based on the population, serum uric acid has been found to be a very important biochemical marker associated with hypertensive individuals. It is apparent from the results of these studies that conditions such as obesity, insulin resistance, dyslipidemia, and high blood pressure, all of which are metabolic problems, can occur together with hyperuricemia. Therefore, it can be assumed that uric acid is part of metabolic disorders and does not exist as an independent risk factor. On the other hand, another reason behind uric acid elevation and decreased urate excretion from the kidney could be dysfunctional insulin signaling. Furthermore, increased consumption of fructose and calories has been shown to lead to high uric acid production.⁽⁴³⁾

Research conducted in 2023 in a longitudinal study demonstrates that high concentrations of

uric acid could be associated with the transition from pre-hypertension to established hypertension. High baseline levels of uric acid are associated with a greater likelihood of developing long-term hypertension over the course of time. This finding suggests that uric acid could play a role in the early stages of disease development. The pathophysiology could be due to vascular remodeling and chronic low-level inflammation, which leads to endothelial injury. It is followed by arterial stiffening and increasing blood pressure over time. Moreover, hypertension can be associated with the renin-angiotensin system as well. ⁽⁴⁴⁾

The serum uric acid levels among hypertensive patients were analyzed by researchers in 2023. It was found out that individuals suffering from complications such as ventricular hypertrophy, stroke, and renal disorders usually have a substantially high level of uric acid. This indicates that target organ injury and disease severity may both be connected to serum uric acid. Reduced renal function, which decreases uric acid excretion and results in buildup in the blood, is a significant contributing cause. Moreover, these patients may experience faster vascular and cardiac damage due to chronic inflammation and oxidative stress. According to these studies, serum uric acid may have prognostic significance for hypertensive individuals. ⁽⁴⁵⁾

Between normotensive and hypertensive individuals, comparative research from 2022 has consistently demonstrated that hypertensive patients have much greater serum uric acid levels. The high level of uric acid might be involved in vascular disorders via multiple ways, as stated in the present study. Oxidative stress that leads to damaging endothelial cells and reduced levels of nitric oxide is one of the primary pathways. This causes increased peripheral vascular resistance and impaired vasodilation. Furthermore, high levels of uric acid can play an important part in thickening arteries by promoting the growth of smooth muscle cells within the vessel wall. Such physiological changes ultimately cause constant elevation of blood pressure. The study proves the theory that uric acid plays an important part in development of hypertension. ⁽⁴⁶⁾

The articles from 2022 that serve as reviews explain the biological importance of uric acid for cardiovascular diseases, particularly high blood pressure. This acid is described as having both protective and damaging roles within the body. The uric acid can act as an antioxidant at physiological levels but functions as a pro-oxidant when present in higher amounts. The uric acid leads to oxidative stress, inflammation, and endothelial dysfunction in conditions such as hyperuricemia. Uric acid also activates the renin-angiotensin-aldosterone system. These mechanisms collectively encourage vascular remodeling, sodium retention, and vasoconstriction. As a result, uric acid is regarded as both a biomarker and a potential mediator in the development of hypertension. ⁽⁴⁷⁾

Untreated hypertensive patients' serum uric acid levels have been assessed in clinical observational studies performed in 2021. According to these findings, those who have been newly diagnosed or are untreated typically have considerably greater uric acid levels than those who are getting treatment. This indicates that antihypertensive medication may positively affect uric acid metabolism or renal excretion. It may also suggest that metabolic abnormalities are significantly related to early-stage hypertension. High uric acid levels in these individuals may also be a result of decreased kidney function and increased oxidative stress. These findings highlight the value of assessing serum uric acid at the time a hypertension diagnosis is made. ⁽⁴⁸⁾

In 2021, research examined the link between hypertensive patients' dietary choices and their blood uric acid levels. A higher concentration of serum uric acid has been linked to a high intake of purine-rich foods, including red meat, seafood, and organ meats. Moreover, elevated purine metabolism has been connected to excessive uric acid generation as a result of a diet rich in fructose. Through inflammatory and metabolic pathways, these dietary factors may also lead to high blood pressure. According to the findings, lifestyle and nutritional adjustments are crucial in managing both uric acid levels and the risk of hypertension. Therefore, dietary counseling is an essential component of hypertension management. ⁽⁴⁹⁾

Gender disparities in serum uric acid levels among hypertensive individuals were brought to light by research done in 2021. It is evident that in most cases, males have higher levels of uric acid compared to females in the study carried out. This is mainly because of the presence of estrogen whose effects make women uric acid secretors, and hence have low uric acid levels. However, when women reach menopause, they have lower estrogen levels, thus increasing their uric acid levels. Therefore, there is no big difference between men and women in uric acid levels in the older group of age.⁽⁵⁰⁾

Cross-sectional studies performed in the year 2020 examined the relationship between blood pressure control and serum uric acid levels. The higher level of uric acid in patients with hypertension being poorly controlled has been established through these studies in comparison to people with effectively managed hypertension. This means that there is a chance of using uric acid as a marker of responsiveness to treatment and condition's severity. In addition, poor blood pressure control may also indicate renal failure or metabolic disturbance.⁽⁵¹⁾

Investigations carried out in 2020 have analyzed the correlation between hypertensive patients' serum uric acid levels and their renal health. As depicted in these researches, there is notable negative correlation between serum uric acid level and the glomerular filtration rate. The study indicates that poor renal health decreases the ability to excrete uric acid, resulting in its accumulation in blood. On the other hand, elevated uric acid level deteriorates the kidneys' vascular system. The study highlights a mutual relationship between high blood pressure, renal failure, and hyperuricemia.⁽⁵²⁾

Sera uric acid levels have been investigated for their use in assessing cardiovascular risks among hypertensive individuals in epidemiological studies undertaken in the year 2020. These studies indicate that higher serum uric acid levels are associated with a variety of risk factors in relation to cardiovascular disease, including obesity, insulin resistance, dyslipidemia, and metabolic

syndrome. This shows that uric acid level assessment represents an overall metabolic condition and not simply an individual component. Therefore, in hypertensive patients, high uric acid levels may indicate a heightened risk of systemic cardiovascular disease. These results endorse its inclusion as an additional biomarker in a thorough evaluation of cardiovascular risk.⁽⁵³⁾

CHAPTER 3 METHODOLOGY

Study Methodology

This was a cross-sectional analytical investigation.

Study Environment

The Department of Pathology/Clinical Laboratory at the City Care Lab in Sargodha conducted the research.

Study Group

Hypertensive patients who visited the lab during the study period made up the study population.

Requirements for Inclusion

Included were identified instances of hypertension (according to established clinical criteria).

Both male and female patients were represented.

Age group of 20 to onward were represented.

Patients who were willing to participate and gave their informed consent in writing were included.

Exclusionary Factors

Patients with known renal illness were not included.

Patients who had previously experienced gout were not included.

Patients suffering from diabetes mellitus were not included.

Patients with long-term liver illness were excluded.

Patients who used drugs that altered uric acid levels, such diuretics, uricosuric drugs, and allopurinol, were not included.

Not included were expectant mothers.

Patients who refused to participate were not included.

Number of Participants

The sample size of 343 hypertensive individuals was determined using a conventional sample size calculation method.

Confidence Level	95%
Margin of Error	5%
Population Proportion	66.4%
Population Size	250,000,000

Gathering data

A pre-designed structured questionnaire was used to collect the data.

Age and gender were among the demographic factors that were documented.

Among the clinical variables recorded were systolic and diastolic blood pressure readings, length of hypertension, and pertinent medical history.

Collected all data in accordance with standard procedures.

Following sterile procedures, venous blood samples were taken.

Lab Analysis

Testing done

The amount of uric acid in the serum was calculated.

Approach Taken

Serum uric acid was determined using the enzymatic colorimetric technique (Uricase-Peroxidase method) in accordance with the manufacturer's instructions.

Procedure Prior to Analysis

Patient Preparation

The test did not require fasting.

Prior to collecting the sample, each participant received a thorough explanation of the procedure. Before participation in the research, informed written consent was obtained.

Collecting Samples

From each participant, between 3 and 5 milliliters of venous blood were obtained.

The specimens were taken using serum separator tubes (SST) or plain tubes.

Sample collection was done while adhering to standard aseptic procedures.

Processing Samples

Blood samples were left to clot for 15–20 minutes at room temperature.

The samples were then centrifuged for five minutes at 3000 rpm.

Using a micropipette, the clear serum was gently separated.

Keeping Samples

Whenever feasible, serum specimens were analyzed right away.

Samples were preserved at 2–8°C for up to 72 hours if immediate analysis was not possible.

The serum samples were stored at –20°C until they could be analyzed for a longer period of time.

Blood Serum Uric Acid Test

Principal

The enzyme uricase converted the uric acid in the sample into hydrogen peroxide and allantoin through oxidation.

A colored quinoneimine molecule was produced when hydrogen peroxide interacted with a chromogenic substrate in the presence of peroxidase.

The color intensity was measured spectrophotometrically and was proportional to the uric acid concentration in the sample.

Method (Enzymatic)

Before testing, all serum samples and reagents were allowed to reach room temperature.

The test tubes were correctly labeled as test, standard, and blank.

Reagents were made and applied in accordance with the manufacturer's instructions.

The test tube received patient serum, the standard tube received standard solution, and the empty tube received distilled water.

The tubes were all incubated at 37°C for 5 to 10 minutes after being softly mixed. Using a spectrophotometer or semi-automated analyzer, absorbance was measured at a wavelength between 520 and 550 nm.

Interpreting the Outcome

Serum uric acid's normal reference ranges were:

3. 4-7. 0 mg/dL for males

2. 4-6. 0 mg/dL for Females

Higher than usual values were thought to be elevated and suggestive of a link between hypertension and an elevated risk of cardiovascular disease.

Data Analysis

Statistical Package for the Social Sciences (SPSS) software was used to input and analyze all acquired data.

Mean \pm standard deviation (SD) was used to represent quantitative variables.

Percentages and frequencies were used to express qualitative variables.

The Chi-square test and independent t-test were among the statistical analyses used when necessary.

A p-value of 0. 05 or less was deemed statistically significant.

Process Following Analysis

Before reporting, all outcomes were validated and verified.

Laboratory data was kept in an organized manner.

Throughout the study, patient privacy was maintained with the utmost care.

Every piece of biohazardous waste was disposed of in accordance with accepted biosafety procedures. The worried physician was informed of the findings for more treatment.

Quality Control and Safety

The investigation adhered to standard operating procedures (SOPs).

At all times, we wore personal protective equipment (PPE), such as lab coats and gloves.

With every batch of analysis, samples of internal quality control were run to guarantee accuracy and precision.

Laboratory equipment was kept well-maintained and calibrated on a regular basis.

Hemolyzed, lipemic, and icteric specimens were avoided to minimize the occurrence of errors during analysis.

CHAPTER 4

RESULTS

The findings of this current study are described in this chapter in an organized manner. Appropriate statistical techniques were applied to analyze the gathered data, which were subsequently presented in table and figure format. The analysis made in this chapter involves descriptive and inferential analyses of the variables under investigation. Findings are discussed in a noninterpretive manner, thus presenting the reader with an objective look at the results obtained from the data.

Table 1 Demographic Characteristics of Study Participants (n = 343)


Variable	Category	Frequency (n)	Percentage (%)
Gender	Male	176	51.3
	Female	167	48.7
Age Group	Group 1	128	37.3
	Group 2	121	35.3
	Group 3	94	27.4
BP Status	Normotensive	100	29.2
	Hypertensive	243	70.8
Total		343	100

Demographic distribution of the participants involved in the research has been provided below.

In total, out of 343 participants, there were 167 individuals (48. 7%) female and 176 (51. 3%)

male. Age groups one (37. 3%), age group two (35. 3%), and age group three (27. 4%) were the three most frequent age groups, in order. Regarding the

condition of the participants, there were 100 individuals (29. 2%) normotensive and 243 (70. 8%) hypertensive.




Graph 1 Distribution of participants by gender, age group, and blood pressure status.

Table 2 Descriptive Statistics of Clinical Parameters Among Study Participants

Parameter	N	Minimum	Maximum	Mean ± SD
Systolic Blood Pressure (mmHg)	343	100	190	148.81 ± 27.99
Diastolic Blood Pressure (mmHg)	343	60	120	95.30 ± 18.36
Serum Uric Acid (mg/dL)	343	2.03	10.49	6.93 ± 2.66

The descriptive statistics for important clinical variables are summarized in this table. The average diastolic blood pressure was 95. 30 ± 18. 36 mmHg, while the average systolic blood pressure was 148. 81 ± 27. 99 mmHg. Participants' average

serum uric acid levels were 6. 93 ± 2. 66 mg/dL. These results align with the significant percentage of hypertensive individuals, showing greater average blood pressure levels in the research sample.




Graph 2 Mean values of systolic BP, diastolic BP, and serum uric acid.

Table 3 Comparison of Serum Uric Acid Levels Between Normotensive and Hypertensive Individuals

Group	N	Mean ± SD (mg/dL)	p-value
Normotensive	100	5.73 ± 2.79	<0.001
Hypertensive	243	7.42 ± 2.44	<0.001

The table displays a comparison of average serum uric acid levels between hypertensive and normotensive groups. Compared to normotensive people (5.73 ± 2.79 mg/dL), hypertensive patients had a significantly higher mean serum

uric acid level (7.42 ± 2.44 mg/dL). There was a statistically significant difference (p < 0.001), indicating a close relationship between elevated serum uric acid levels and hypertension.




Graph 3 Comparison of mean serum uric acid levels between normotensive and hypertensive groups.

Table 4 Correlation of Serum Uric Acid with Systolic and Diastolic Blood Pressure

Variables	Pearson Correlation (r)	p-value	N
Uric Acid vs Systolic BP	0.283	<0.001	343
Uric Acid vs Diastolic BP	0.277	<0.001	343
Systolic BP vs Diastolic BP	0.836	<0.001	343

The relationship between blood pressure measurements and serum uric acid levels is shown in the table. Diastolic blood pressure ($r = 0.277$, $p < 0.001$) and systolic blood pressure ($r = 0.283$, $p < 0.001$) both had a positive but modest correlation with serum uric acid. Moreover, there

was a substantial positive relationship between systolic and diastolic blood pressure ($r = 0.836$, $p < 0.001$). Increased serum uric acid levels are correlated with higher blood pressure values, according to statistical analysis of all correlations.



Graph 4 Correlation between serum uric acid and blood pressure parameters.

CHAPTER 4 DISCUSSION

Serum uric acid was tested as a marker in hypertensive individuals in the current study. Because of its complications, hypertension is a major global health issue and is linked to high morbidity and mortality, especially in cardiovascular and renal disorders. In recent years, serum uric acid (SUA) has become a possible biomarker associated with hypertension and its development. This study, then, sought to assess the link between blood pressure and serum uric acid levels in persons with hypertension.

In this study, there were 343 subjects overall, with a roughly equal gender split between men (51.3%) and women (48.7%). Most of the subjects were hypertensive (70.8%) while the remaining subjects were normotensive (29.2%). As there were many hypertensive subjects in the study sample, the average systolic and diastolic blood pressure readings were very high.

One of the most significant observations from the current study is the presence of high SUA concentrations in hypertensive patients compared to normotensive subjects. There is a strong relationship between increased serum uric acid

concentration and hypertension, as demonstrated by the above observation. Indeed, other studies conducted on different samples also indicate that patients with hypertension tend to have elevated uric acid concentration. It confirms the relationship between serum uric acid and blood pressure.

Moreover, there exists a significant relationship between serum uric acid and both systolic and diastolic blood pressure. Even though the relationship is quite weak, it is significant, and thus indicates a relationship between increased uric acid concentration and blood pressure. Other studies have reached a similar conclusion regarding the relationship between blood pressure variables and uric acid concentration.

The findings can be attributed to some biological processes that occur. The rise in uric acid concentration in the serum can affect the functioning of the endothelium since it decreases the amount of nitric oxide required for relaxation of blood vessels. Moreover, uric acid can stimulate oxidative stress, inflammation, and activation of renin-angiotensin-aldosterone system, leading to hypertension and increased vascular resistance. It can be said that, through these mechanisms, the uric acid can be involved not only in association with hypertension but also in its development and progression.

Besides, high levels of uric acid have been connected to poor sodium elimination and damage to renal micro vessels, which can aggravate the development of the disease. Thus, the physiological impacts indicate the role of the compound in the pathology itself rather than being just a marker.

In terms of clinical practice, the findings of the research demonstrate the importance of measuring serum uric acid levels among patients with hypertension. The test is simple, cheap, and available, making it easily applicable in routine clinical practice. Checking SUA levels can help detect more at-risk patients, who should be subjected to early management of their condition and its complications.

However, some of the constraints associated with the study should be acknowledged. First, since it is cross-sectional research, it is unable to establish

causality between serum uric acid and hypertension. Second, conducting the study in one particular place means that the applicability of the findings obtained from this study is questionable. Also, other variables such as diet, physical activity, and hereditary vulnerability need further analysis.

Overall, according to the above discussion, the study under analysis highlights a significant connection between increased serum uric acid and hypertension. The fact that hypertensive patients exhibit increased levels of SUA, as well as the positive correlation of the variable with blood pressure, suggests that uric acid can serve as a potential marker in studying and treating hypertension. Longitudinal studies are recommended in order to explore the connections and therapeutic implications.

CHAPTER 6 CONCLUSION

Objectives of this study were to ascertain the usefulness of serum uric acid as a marker for hypertension. Findings from this study showed that serum uric acid was significantly higher in hypertensive individuals than normotensive individuals. This indicates an existing link between blood uric acid and hypertension.

In addition, serum uric acid had a significant positive correlation with systolic blood pressure and diastolic blood pressure. Relationship between increased uric acid and increased blood pressure is evident from the fact that the correlation was weak. This finding supports the hypothesis that serum uric acid might be associated with the pathogenesis of hypertension. Moreover, the study highlights the potential use of serum uric acid as a simple, cheap, and easily accessible biological marker. Identification of patients who are susceptible to high blood pressure can be achieved by determining their serum uric acid, which will also contribute to improved disease monitoring and management.

In summary, results from this study show a strong association between serum uric acid and hypertension, and hence its use as an important marker for hypertensive patients.

Limitations of the Study

Limitations in the present study, although providing meaningful information, include the following:

- As the study was cross-sectional in nature, it would be hard to establish whether or not there is any causality between serum uric acid and hypertension.
- Owing to the fact that the study was performed using a single center, the applicability of the results to the entire population can be considered limited.
- While adequate enough, the sample size used in the study was relatively small and probably did not capture the complete population.
- Some factors, such as diet, lifestyle, socio-economic status, and genetical predisposition, were not assessed thoroughly.
- Despite the exclusion of individuals with diseases that could alter their levels of serum uric acid, the results obtained can be influenced by other undetected conditions..

Recommendations

Below is a list of recommendations which have been made considering the outcome of the present study:

- For improved risk assessment and treatment, serum uric acid testing should be regarded as a regular procedure in individuals with high blood pressure.
- To spot patients at a higher risk of complications, clinicians should check uric acid levels in addition to blood pressure.
- Lifestyle changes, such dietary adjustments, weight management, and physical activity, should be encouraged to manage both hypertension and uric acid levels.
- In order to confirm the results and enhance generalizability, additional large-scale, multicenter trials are advised.
- To demonstrate a link between serum uric acid and hypertension, cohort and longitudinal studies should be performed.
- The impact of uric acid-lowering treatments on cardiovascular outcomes and blood pressure management should be investigated in future studies.

REFERENCES

- Whelton, P. K., Carey, R. M., Aronow, W. S., et al. (2018). 2017 ACC/AHA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. *Hypertension*, 71(6), e13–e115. <https://doi.org/10.1161/HYP.0000000000000065>
- Mills, K. T., Stefanescu, A., & He, J. (2020). The global epidemiology of hypertension. *Nature Reviews Nephrology*, 16(4), 223–237. <https://doi.org/10.1038/s41581-019-0244-2>
- Williams, B., Mancia, G., Spiering, W., et al. (2018). 2018 ESC/ESH guidelines for the management of arterial hypertension. *European Heart Journal*, 39(33), 3021–3104. <https://doi.org/10.1093/eurheartj/ehy339>
- Forouzanfar, M. H., et al. (2017). Global burden of hypertension. *JAMA*, 317(2), 165–182. <https://doi.org/10.1001/jama.2016.19043>
- Carretero, O. A., & Oparil, S. (2000). Essential hypertension. *Circulation Research*, 87(7), 520–529. <https://doi.org/10.1161/01.RES.87.7.520>
- Oparil, S., et al. (2018). Hypertension. *Nature Reviews Disease Primers*, 4, 18014. <https://doi.org/10.1038/nrdp.2018.14>
- Ehret, G. B., & Caulfield, M. J. (2013). Genes for blood pressure: An opportunity to understand hypertension. *European Heart Journal*, 34(13), 951–961. <https://doi.org/10.1093/eurheartj/ehs455>
- Franklin, S. S., et al. (1997). Hemodynamic patterns of age-related blood pressure changes. *Circulation*, 96(1), 308–315. <https://doi.org/10.1161/01.CIR.96.1.308>
- Hall, J. E., et al. (2015). Obesity-induced hypertension: Interaction of neurohumoral and renal mechanisms. *Circulation Research*, 116(6), 991–1006. <https://doi.org/10.1161/CIRCRESAHA.116.305697>

- He, F. J., & MacGregor, G. A. (2014). Salt reduction lowers cardiovascular risk. *Journal of Human Hypertension*, 28(6), 345–352.
<https://doi.org/10.1038/jhh.2013.112>
- Appel, L. J., et al. (2006). Dietary approaches to prevent and treat hypertension. *Hypertension*, 47(2), 296–308.
<https://doi.org/10.1161/01.HYP.0000202568.01167.B6>
- Rimoldi, S. F., Scherrer, U., & Messerli, F. H. (2014). Secondary arterial hypertension. *European Heart Journal*, 35(19), 1245–1254.
<https://doi.org/10.1093/eurheartj/ehu121>
- Dzau, V. J., & Balatbat, C. A. (2019). Future of hypertension. *Hypertension*, 74(3), 450–457.
<https://doi.org/10.1161/HYPERTENSIONAHA.119.12702>
- Levy, D., et al. (1996). Hypertension and heart failure progression. *JAMA*, 275(20), 1557–1562.
<https://doi.org/10.1001/jama.1996.03530440037034>
- O'Donnell, M. J., et al. (2010). Stroke risk factors. *The Lancet*, 376(9735), 112–123.
[https://doi.org/10.1016/S0140-6736\(10\)60834-3](https://doi.org/10.1016/S0140-6736(10)60834-3)
- Ku, E., et al. (2019). Hypertension in chronic kidney disease. *American Journal of Kidney Diseases*, 74(1), 120–131.
<https://doi.org/10.1053/j.ajkd.2018.12.044>
- Wong, T. Y., & Mitchell, P. (2004). Hypertensive retinopathy. *New England Journal of Medicine*, 351(22), 2310–2317.
<https://doi.org/10.1056/NEJMra032865>
- Maiuolo, J., et al. (2016). Uric acid metabolism and excretion. *International Journal of Cardiology*, 213, 8–14.
<https://doi.org/10.1016/j.ijcard.2015.08.109>
- Mandal, A. K., & Mount, D. B. (2015). Molecular physiology of uric acid. *Annual Review of Physiology*, 77, 323–345.
<https://doi.org/10.1146/annurev-physiol-021014-071714>
- Richette, P., & Bardin, T. (2010). Gout. *The Lancet*, 375(9711), 318–328.
[https://doi.org/10.1016/S0140-6736\(09\)60883-7](https://doi.org/10.1016/S0140-6736(09)60883-7)
- Sautin, Y. Y., & Johnson, R. J. (2008). Uric acid paradox. *Nucleosides, Nucleotides and Nucleic Acids*, 27(6–7), 608–619.
<https://doi.org/10.1080/15257770802138558>
- Feig, D. I., Kang, D. H., & Johnson, R. J. (2008). Uric acid and cardiovascular risk. *New England Journal of Medicine*, 359(17), 1811–1821.
<https://doi.org/10.1056/NEJMra0800885>
- Grayson, P. C., et al. (2011). Hyperuricemia and hypertension meta-analysis. *Arthritis Care & Research*, 63(1), 102–110.
<https://doi.org/10.1002/acr.20344>
- Khosla, U. M., et al. (2005). Uric acid endothelial dysfunction. *Kidney International*, 67(5), 1739–1742.
<https://doi.org/10.1111/j.1523-1755.2005.00253.x>
- Sautin, Y. Y., et al. (2007). Uric acid inflammation role. *American Journal of Physiology-Cell Physiology*, 293(2), C584–C596.
<https://doi.org/10.1152/ajpcell.00600.2006>
- Mazzali, M., et al. (2001). Uric acid increases blood pressure mechanism. *Hypertension*, 38(5), 1101–1106.
<https://doi.org/10.1161/hy1101.093095>
- Johnson, R. J., et al. (2005). Uric acid hypertension mechanism. *Hypertension*, 45(1), 18–20.
<https://doi.org/10.1161/01.HYP.0000150785.66578.0f>
- Sundström, J., et al. (2005). Uric acid and hypertension incidence. *Hypertension*, 45(1), 28–33.
<https://doi.org/10.1161/01.HYP.0000150785.08867.41>

- Borghgi, C., et al. (2015). Uric acid cardiovascular risk review. *Journal of Hypertension*, 33(9), 1729-1741.
<https://doi.org/10.1097/HJH.00000000000000701>
- Sautin, Y. Y., & Johnson, R. J. (2008). Uric acid biomarker paradox. *Nucleosides, Nucleotides and Nucleic Acids*, 27(6-7), 608-619.
<https://doi.org/10.1080/15257770802138558>
- Feig, D. I., et al. (2008). Uric acid predictive role. *New England Journal of Medicine*, 359(17), 1811-1821.
<https://doi.org/10.1056/NEJMra0800885>
- Borghgi, C., et al. (2015). Serum uric acid clinical role. *Journal of Hypertension*, 33(9), 1729-1741.
<https://doi.org/10.1097/HJH.00000000000000701>
- Grayson, P. C., et al. (2011). Meta-analysis uric acid hypertension. *Arthritis Care & Research*, 63(1), 102-110.
<https://doi.org/10.1002/acr.20344>
- Johnson, R. J., et al. (2003). Pathogenetic role of uric acid. *Hypertension*, 41(6), 1183-1190.
<https://doi.org/10.1161/01.HYP.0000069700.62727.C5>
- Li, M., et al. (2019). Hyperuricemia hypertension meta-analysis. *Journal of Clinical Hypertension*, 21(11), 1604-1612.
<https://doi.org/10.1111/jch.13690>
- Feig, D. I., et al. (2008). Confounding factors uric acid. *New England Journal of Medicine*, 359(17), 1811-1821.
<https://doi.org/10.1056/NEJMra0800885>
- Khan, M. A., & Qureshi, A. R. (2016). Hyperuricemia and hypertension: Evidence from a Pakistani population study. *Pakistan Journal of Medical Sciences*, 32(2), 389-393.
<https://doi.org/10.12669/pjms.322.9276>
- Borghgi, C., et al. (2015). Lack of standardized cutoff uric acid. *Journal of Hypertension*, 33(9), 1729-1741.
<https://doi.org/10.1097/HJH.00000000000000701>
- Feig, D. I., Kang, D. H., & Johnson, R. J. (2021). Uric acid and cardiovascular risk. *New England Journal of Medicine*, 384(7), 630-639.
<https://doi.org/10.1056/NEJMra0800885>
- Grayson, P. C., Kim, S. Y., LaValley, M., & Choi, H. K. (2020). Hyperuricemia and incident hypertension: A systematic review and meta-analysis. *Arthritis Care & Research*, 72(1), 64-72. <https://doi.org/10.1002/acr.23883>
- Li, X., Meng, X., Timofeeva, M., et al. (2021). Serum uric acid and risk of hypertension in a prospective cohort study. *Hypertension Research*, 44(5), 567-575.
<https://doi.org/10.1038/s41440-020-00568-9>
- Borghgi, C., Agabiti-Rosei, E., Johnson, R. J., et al. (2022). Serum uric acid and cardiovascular disease: A position statement. *Journal of Hypertension*, 40(3), 384-392.
<https://doi.org/10.1097/HJH.000000000000003050>
- Juraschek, S. P., Kovell, L. C., Miller, E. R., & Gelber, A. C. (2020). Effects of uric acid on blood pressure and cardiovascular risk. *Hypertension*, 75(2), 439-445.
<https://doi.org/10.1161/HYPERTENSIO.NAHA.119.14086>
- Chen, L., Zhu, W., & Zhang, Y. (2021). Association between serum uric acid and progression of prehypertension to hypertension. *Journal of Clinical Hypertension*, 23(9), 1645-1652.
<https://doi.org/10.1111/jch.14350>
- Sundström, J., Sullivan, L., D'Agostino, R. B., et al. (2022). Serum uric acid and risk of cardiovascular complications in hypertension. *Hypertension*, 79(4), 812-820.
<https://doi.org/10.1161/HYPERTENSIO.NAHA.121.18654>
- Gherghina, M. E., Peride, I., Tiglis, M., & Neagu, T. P. (2020). Uric acid and hypertension: Pathophysiological mechanisms. *International Journal of Molecular Sciences*, 21(11), 4238.
<https://doi.org/10.3390/ijms21114238>

- Kuwabara, M., Niwa, K., & Hisatome, I. (2021). Uric acid and hypertension: From experimental models to clinical practice. *Nutrients*, 13(11), 4115. <https://doi.org/10.3390/nu13114115>
- Li, M., Hu, X., Fan, Y., et al. (2020). Serum uric acid and risk of hypertension: A population-based study. *Scientific Reports*, 10, 1301. <https://doi.org/10.1038/s41598-020-58149-7>
- Zhou, Y., Fang, L., Jiang, J., et al. (2021). Dietary factors and serum uric acid in hypertensive patients. *Nutrients*, 13(7), 2375. <https://doi.org/10.3390/nu13072375>
- Wang, J., Qin, T., Chen, J., et al. (2020). Gender differences in serum uric acid and hypertension risk. *BMC Cardiovascular Disorders*, 20, 512. <https://doi.org/10.1186/s12872-020-01761-9>
- Zhang, W., Sun, K., Yang, Y., et al. (2021). Serum uric acid and blood pressure control in hypertensive patients. *American Journal of Hypertension*, 34(6), 614–621. <https://doi.org/10.1093/ajh/hpab012>
- Johnson, R. J., Bakris, G. L., & Borghi, C. (2020). Hyperuricemia, hypertension, and kidney disease. *Kidney International*, 97(5), 771–779. <https://doi.org/10.1016/j.kint.2019.11.021>
- Ryu, S., Kim, H. C., & Choi, H. K. (2022). Uric acid and cardiovascular risk: Updated evidence. *Circulation Journal*, 86(3), 345–352. <https://doi.org/10.1253/circj.CJ-21-0725>